Press Releases

Elcelyx Therapeutics Reports Positive Results in Phase 2b Study of Metformin Delayed Release in Type 2 Diabetes
November 10, 2016
Elcelyx Therapeutics Elects Sandy Mahatme to Board of Directors
October 12, 2016
Elcelyx Therapeutics Completes Enrollment in Phase 2b Clinical Trial of Metformin Delayed Release for Type 2 Diabetes
May 25, 2016
Elcelyx Therapeutics Announces $40 Million Series E Financing
October 1, 2015
Diabetes drug Metformin’s primary effect is in the gut, not the bloodstream
August 18, 2015
Elcelyx Therapeutics to Present Metformin DR Data at American Diabetes Association 75th Scientific Sessions
June 6, 2015
Elcelyx Therapeutics Announces Positive Results in Phase 2b Study of NewMet in Type 2 Diabetes
October 21, 2013
Elcelyx Therapeutics to Present Clinical Data on NewMet™ in Type 2 Diabetes at the 49th Annual European Association for the Study of Diabetes Meeting
September 17, 2013
NaZura BioHealth Spun-out from Elcelyx Therapeutics to Advance Lovidia for Weight Management
September 4, 2013
Elcelyx Therapeutics’ NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
September 4, 2013
Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
June 22, 2013
Elcelyx Therapeutics to Present Clinical Data on NewMet™ in Type 2 Diabetes at the 2013 American Diabetes Association Scientific Sessions
June 14, 2013
Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
May 20, 2013
Elcelyx Therapeutics Extends Series B Financing for Late-Stage Clinical Programs in Weight Loss and Diabetes
August 13, 2012
Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
August 13, 2012